Reduced Risk of Major Cardiovascular Events Clinical trials, such as the SUSTAIN-6 and PIONEER-6 studies, have demonstrated that Semaglutide can reduce the risk of major cardiovascular events, such as heart attack, stroke, and cardiovascular-related death
However, its side effects can differ slightly: Gastrointestinal Discomfort: Nausea, bloating, and stomach pain are common, especially in the first few weeks
The drug was first approved in 2010, but the problem was that a patient had to inject it daily
While berberine may offer modest metabolic benefits, it works through different mechanisms and produces smaller glycemic improvements than prescription GLP-1 medications, which remain the evidence-based standard of care
These are official notices issued when an investigator observes conditions that, in their judgment, may constitute violations of the Food, Drug, and Cosmetic Act